Catatonia: Effectiveness of Transcranial Direct Current Electrostimulation (CATATOES)

Catatonia Clinical Trial

— CATATOES  

Official title:

Catatonia: Effectiveness of Transcranial Direct Current Electrostimulation (CATATOES)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06139432
• Other study ID #: D21-P022
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 1, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: Centre Hospitalier St Anne
• Contact: Alexandre Haroche, MD, PHD
• Phone: (0)145658714
• Email: a.haroche[@]ghu-paris.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Nearly 10% of people hospitalized in psychiatry have a catatonic syndrome. The treatment of this syndrome is based on lorazepam and electro-convulsive therapy (ECT) in drug-resistant forms. ECT is the reference therapy, very effective in catatonia, but remain difficult to access due to the technical platform required for their realization, leading to delays in the implementation of the treatment responsible for an increase in the morbidity and mortality of catatonia. In this context, a new therapeutic tool available in the treatment of drug-resistant catatonia would improve the prognosis of catatonia. Transcranial direct current stimulation (tDCS) is an alternative, non-invasive brain stimulation technique that does not require anesthesia, and inexpensive and has been shown to be effective in depression and schizophrenia. A series of clinical cases suggests its potential efficacy in catatonia. Our objective is to evaluate the efficacy of tDCS in catatonia in a clinical trial.

Description:

Catatonia is a pathology combining affective, motor, behavioural and neuro-vegetative symptoms. Nearly 10% of people hospitalized in psychiatry have a catatonic syndrome. However, it is a severe disorder with a potentially lethal course.

For the treatment of catatonia, lorazepam is effective in most cases, with the percentage of responding patients varying between 70 and 80 per cent, according to the literature. Catatonic episodes resistant to lorazepam are usually associated with chronic catatonia as part of a neurodevelopmental disorder. Genetic abnormalities are often found in these forms of catatonia.

Electroconvulsive therapy (ECT) should be considered for any catatonic episode that is resistant to lorazepam. It is also indicated when a rapid effect must be obtained in life-threatening situations (e.g. malignant catatonia) or when the underlying pathology requires this treatment. Its efficacy is considered excellent, with response rates ranging from 59% to 100%, including when patients have not responded to lorazepam.

There are several limitations to ECT treatment for catatonia:

• There are many centres, particularly in France, where ECT is inaccessible. Delays in access to ECT are particularly acute in rural areas.

• ECT requires a pre-therapeutic assessment, delaying treatment by several days. However, catatonic syndrome is an emergency requiring immediate treatment. Delaying treatment exposes the patient to the risk of aggravation, i.e. malignant catatonia, with a life-threatening outcome.

• ECT treatment is sometimes contraindicated because of contraindications to anaesthesia.

Among neuromodulation techniques, the promising alternative approaches are transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).

Transcranial direct current stimulation (tDCS) is a non-invasive electrical brain stimulation that does not require anaesthesia. The tDCS is based on applying a low direct electrical current (typically less than 20 volts) via two electrodes placed on the scalp. The electric current is applied to the anode (positive electrode) and then flows to the cathode (negative electrode). The electrodes, surrounded by sponges soaked in a saline solution, are positioned at the level of the scalp according to the international 10-20 placement system or, more rarely, according to the MRI-guided neuronavigation system. The device is easily transportable and does not require a specific technical platform.

The present study, randomized versus placebo, aims to test the efficacy of tDCS stimulation on catatonic-resistant syndrome.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men or women over 18 years old

• Under the care of the GHU PARIS Psychiatry and Neurosciences or EPS Ville Evrard.

• Suffering from an episode of catatonia according to the DSM-5 CRITERIA

• Persistence of catatonia criteria according to DSM-5 after 24 hours of lorazepam treatment or contraindication to lorazepam or poor tolerance to lorazepam

• Patient (or guardian) having given informed and written consent

• Beneficiary of a social security plan

Exclusion Criteria:

• Malignant catatonia

• Pregnant or breastfeeding women

• Patients with contraindications to tCDS, namely patients with a defibrillator or a pacemaker, brain stimulator, presence of intracranial metals, uncovered craniectomy or after trepanning.

Related Conditions & MeSH terms

• Catatonia

Intervention

Device:
• Active tDCS
Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system). Cathode opposite the left temporoparietal junction (between T3 and P3). The stimulation level is 2mA for 20 minutes. Sessions are held twice daily on working days (with a minimum of 3 hours between sessions). Twenty sessions will be carried out, two sessions per consecutive working day.
• Sham tDCS
Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system). Cathode opposite the left temporoparietal junction (between T3 and P3). Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation. Sessions are held twice daily on working days (with a minimum of 3 hours between sessions). Twenty sessions will be carried out, two sessions per consecutive working day.

Locations

Country	Name	City	State
France	CRC Pôle 93G03 Etablissement Public de Santé EPS Ville Evrard	Neuilly-sur-Marne	Île-de-France
France	Groupe Hospitalier Universitaire (GHU) Psychiatrie et Neurosciences	Paris	Île-de-France

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier St Anne

Country where clinical trial is conducted

France, 

References & Publications (6)

Haroche A, Giraud N, Vinckier F, Amad A, Rogers J, Moyal M, Canivet L, Berkovitch L, Gaillard R, Attali D, Plaze M. Efficacy of Transcranial Direct-Current Stimulation in Catatonia: A Review and Case Series. Front Psychiatry. 2022 Apr 27;13:876834. doi: 10.3389/fpsyt.2022.876834. eCollection 2022. — View Citation

Hawkins JM, Archer KJ, Strakowski SM, Keck PE. Somatic treatment of catatonia. Int J Psychiatry Med. 1995;25(4):345-69. doi: 10.2190/X0FF-VU7G-QQP7-L5V7. — View Citation

Moyal M, Plaze M, Baruchet A, Attali D, Cravero C, Raffin M, Consoli A, Cohen D, Haroche A, Chaumette B. Efficacity of tDCS in catatonic patients with Phelan McDermid syndrome, a case series. Brain Stimul. 2022 Nov-Dec;15(6):1432-1434. doi: 10.1016/j.brs.2022.10.005. Epub 2022 Oct 26. No abstract available. — View Citation

Sarkar S, Sakey S, Mathan K, Bharadwaj B, Kattimani S, Rajkumar RP. Assessing catatonia using four different instruments: Inter-rater reliability and prevalence in inpatient clinical population. Asian J Psychiatr. 2016 Oct;23:27-31. doi: 10.1016/j.ajp.2016.07.003. Epub 2016 Jul 11. — View Citation

Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G. A clinical review of the treatment of catatonia. Front Psychiatry. 2014 Dec 9;5:181. doi: 10.3389/fpsyt.2014.00181. eCollection 2014. — View Citation

Solmi M, Pigato GG, Roiter B, Guaglianone A, Martini L, Fornaro M, Monaco F, Carvalho AF, Stubbs B, Veronese N, Correll CU. Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. Schizophr Bull. 2018 Aug 20;44(5):1133-1150. doi: 10.1093/schbul/sbx157. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bush-Francis Catatonia Rating Scale (BFCRS)	The BFCRS is a comprehensive tool for diagnosing and assessing the severity of catatonic syndrome.; The BFCRS was devised by Bush, Fink, Petrides, Dowling and Francis in 1996. This scale consists of the assessment of 23 symptoms, scored from 0 to 3. The total score of the BFCRS is the sum of the responses to the 23 items (minimum 0 - maximum 69). High scores reflect a severe disorder.; Improvement is defined by a 30% decrease in BFCRS scores after 5 days of treatment (10 tDCS sessions)	Day 6
Secondary	Bush-Francis Catatonia Rating Scale (BFCRS)	The BFCRS is a comprehensive tool for diagnosing and assessing the severity of catatonic syndrome.; The BFCRS was devised by Bush, Fink, Petrides, Dowling and Francis in 1996. This scale consists of the assessment of 23 symptoms, scored from 0 to 3. The total score of the BFCRS is the sum of the responses to the 23 items (minimum 0 - maximum 69). High scores reflect a severe disorder.; The treatment response is assessed as the absolute reduction of the BCRF score after 20 sessions.	Day 14
Secondary	Effectiveness of active tDCS vs sham: patients in remission after 20 sessions	Percentage of patients who no longer fulfil the DSM-5 criteria for catatonic syndrome. This criterion was assessed at each session between V1 and V14.	every day from Day 1 to Day 14
Secondary	Lorazepam treatment (mg/die)	Lorazepam daily administration in mg/die	At baseline then every day from Day 1 to Day 14
Secondary	Percentage of patients requiring electroconvulsive therapy (ECT)	Percentage of patients requiring electroconvulsive therapy (ECT) during the evaluation period (active vs shamm tDCS)	Every day from Day 1 to Day 14
Secondary	Occurrence of catatonic syndrome complications	Pulmonary embolism confirmed by angioscan, transfer to intensive care, pressure sores, inhalation pneumonia requiring antibiotic therapy, death.	Every day from Day 1 to Day 14
Secondary	To assess the effectiveness of tDCS by comparing changes over time in psychiatric symptomatology: Montgomery-Asberg depression scale (MADRS score)	The Montgomery-Asberg depression scale (MADRS ) is a 10 -item scale used to assess the severity of depression. High scores reflect a severe disorder (score range 0-60).	At baseline, then at Day 1, Day 6, and from Day 11 to Day 14
Secondary	To assess the effectiveness of tDCS by comparing changes over time in psychiatric symptomatology: schizophrenia: . Positive and Negative Syndrome Scale (PANSS score)	PANSS (Positive and Negative Syndrome Scale): is a 30-item scale widely used in schizophrenia research to assess positive and negative psychotic dimensions. The PANSS is composed of 3 subscales: Positive Scale, Negative Scale, and General Psychopathology Scale. Each subscale is rated with 1 to 7 points ranging from absent to extreme. The range for the Positive and Negative Scales is 7-49, and the range for the General Psychopathology Scale is 16-112. The total PANSS score is simply the sum of the sub scales. In addition to these measures, a Composite Scale is scored by subtracting the negative score from the positive score. This yields a bipolar index that ranges from -42 to +42, which is essentially a difference score reflecting the degree of predominance of one syndrome in relation to the other.	At baseline, then at Day 1, Day 6, and from Day 11 to Day 14
Secondary	To assess the effectiveness of tDCS by comparing changes over time in psychiatric symptomatology: hypomanic or manic episode: Young Mania Rating Scale (YMRS score)	The Young Mania Rating Scale (YMRS) is a rating scale used to evaluate manic symptoms : there are eleven items, each item given a severity rating. Four are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale.High scores reflect a severe disorder (score range 0-60)	At baseline, then at Day 1, Day 6, and from Day 11 to Day 14
Secondary	Evolution of physiological parameters: Electrocardiography (ECG)	ECG values for waves and intervals: RR interval(seconds);P wave (milliseconds); PR (milliseconds);PR segment (milliseconds); QRS complex (milliseconds) ;ST segment (milliseconds); T wave:(milliseconds) ;QT interval (milliseconds )	Baseline then every day from Day 1 to Day 14
Secondary	Evolution of physiological parameters: blood pressure (systolic pressure and a diastolic pressure mm HG)	Blood pressure (systolic pressure and a diastolic pressure mm HG)	Baseline then every day from Day 1 to Day 14
Secondary	Evolution of physiological parameters: brething system	Brething system: breaththig freaquency ( breath per minute);	Baseline then every day from Day 1 to Day 14
Secondary	Evolution of physiological parameters: Body temperature °C	Body temperature °C	Baseline then every day from Day 1 to Day 14
Secondary	Evolution of physiological parameters: Skin conductance level (SCL)	Skin conductance level (SCL value µS)	Baseline then every day from Day 1 to Day 14